about
P3373
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitorsThe status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenograftsORegAnno: an open-access community-driven resource for regulatory annotationcisRED: a database system for genome-scale computational discovery of regulatory elements.SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolutionSomatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.ORegAnno 3.0: a community-driven resource for curated regulatory annotationORegAnno: an open access database and curation system for literature-derived promoters, transcription factor binding sites and regulatory variationClonal architectures and driver mutations in metastatic melanomasThe cure: design and evaluation of a crowdsourcing game for gene selection for breast cancer survival predictionOrganizing knowledge to enable personalization of medicine in cancercDNA hybrid capture improves transcriptome analysis on low-input and archived samples'Omic approaches to preventing or managing metastatic breast cancerGenome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencingThe Genome sequence of the SARS-associated coronavirusInformatics for RNA Sequencing: A Web Resource for Analysis on the Cloud.Systematic recovery and analysis of full-ORF human cDNA clones.Statistically identifying tumor suppressors and oncogenes from pan-cancer genome-sequencing dataAssessment and integration of publicly available SAGE, cDNA microarray, and oligonucleotide microarray expression data for global coexpression analyses.Sequence biases in large scale gene expression profiling data.A survey of genomic properties for the detection of regulatory polymorphisms.Diagnostic utility of galectin-3 in thyroid cancer.Identification of gene regulation patterns underlying both oestrogen- and tamoxifen-stimulated cell growth through global gene expression profiling in breast cancer cells.Identification of PADI2 as a potential breast cancer biomarker and therapeutic target.F11R is a novel monocyte prognostic biomarker for malignant gliomaRNA-sequencing reveals oligodendrocyte and neuronal transcripts in microglia relevant to central nervous system disease.Lrig1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ERα-positive breast cancer.Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast CancerGenome Modeling System: A Knowledge Management Platform for Genomics.Optimizing cancer genome sequencing and analysis.Loss of cell-surface laminin anchoring promotes tumor growth and is associated with poor clinical outcomes.Lectin chromatography/mass spectrometry discovery workflow identifies putative biomarkers of aggressive breast cancers.Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia.DGIdb 2.0: mining clinically relevant drug-gene interactions.Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers.Text-mining assisted regulatory annotationc-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells.Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers.
P50
Q21184033-992A6B47-40C6-4B38-8E90-810DF840ADF4Q24307426-62B4375C-D2FA-4385-87B2-CF9116E16164Q24621116-4FD7C71B-4907-4AE9-B6FA-873D31C9F588Q24648942-5CBE1B3F-661F-4093-B46B-4D08078F4AC1Q25254981-24C1DF2A-824E-4DE7-AD65-BE0CBC66046DQ27321859-E525A555-2BED-42DB-B829-1D3EBE5DE2C1Q27851546-399136B2-732D-4941-A568-C3EF3A4842CDQ28269966-EFB95178-A501-472E-9843-97EE9CF2302BQ28290181-D988F11C-8CF4-4492-9F0A-34DD9C04098EQ28544919-C6BE89FD-875B-4767-A62B-6464FA868CD0Q28651478-F20086C3-FB52-4A75-950E-53EAB632FA6FQ28652806-3AF22D7B-8293-443E-A005-0028B280BD2BQ28656404-706F8B62-01B0-4010-AF7E-DE2B443F3A86Q28730572-6F4EF44D-700F-4124-9E5D-544BCDB2ECAAQ29618021-1E766305-C13A-4A85-AA8F-E755B75A0BF9Q29619007-8F087049-619D-4B9F-94B6-DB29A78695A6Q30488189-7022E91F-C465-4C49-BC22-B6081635710FQ30841716-AD960123-874F-4BCE-826B-6FB5077754F9Q30982579-1AD88021-A637-42BF-8343-984D76EFD147Q30999749-67CE8E64-9B04-432C-B489-80834F41C752Q31048727-51979BE9-49C2-4913-8825-B45499A98FF5Q33287187-F733D710-E987-4CBD-B5FC-E998AB1CD2E0Q33816239-76BDE889-51E9-483B-8FE1-DB2F4E88BB3FQ34411166-A1C68C5E-06E0-4286-8BE1-B24A8200312CQ34461456-00ED7998-850B-4AA0-8406-3826F2CA5455Q35023227-C00319C0-EA0B-4E3F-97C4-ECEF683D6AB8Q35091456-D0ADAFFC-4169-4C2B-8E58-28BA69535FE0Q35386137-2363CECA-5009-4AB5-95CA-F55A50663513Q35693389-3E200AEE-F972-4867-8308-F5A8FC1E0871Q35836071-FA823C03-D132-4AE2-A9DE-0ABB8B621FF6Q35863001-5B4BA70F-ACC7-4D70-B0AD-28ED927A67DFQ35967522-579B0054-9BDA-42FF-899F-77C936B2FCDEQ36058024-E12AE701-4A3E-4827-BE10-0C18AE25FE50Q36195450-30438502-28C4-4FDF-B355-80DF5B6C796DQ36208652-1FD647F2-636A-4A10-A8D1-99FC180D87CCQ36434749-37D462BE-7C52-4081-99F0-B39A343E41DDQ36639451-EE167146-8197-4362-9220-54B9DEC5F34CQ36642396-093A5AE7-9550-478E-B523-EBAF1E2AFE65Q37025060-91CF2DB9-40F2-4AF8-A474-16C7571F2B24Q37113145-1FB1DAD2-368C-47D9-8956-A4684A772FC1
P50
description
Canadian oncologist
@en
Canadian oncologist
@en-ca
Canadian oncologist
@en-gb
kanadischer Onkologe
@de
oncólogo canadiense
@es
oncólogu canadianu
@ast
طبيب أورام كندي
@ar
name
Obi Griffith
@ca
Obi Griffith
@en
Obi Griffith
@es
Obi Griffith
@fr
Obi Griffith
@ga
Obi Griffith
@sq
Obi L Griffith
@nl
Obi L Griffith
@sl
type
label
Obi Griffith
@ca
Obi Griffith
@en
Obi Griffith
@es
Obi Griffith
@fr
Obi Griffith
@ga
Obi Griffith
@sq
Obi L Griffith
@nl
Obi L Griffith
@sl
altLabel
Obi L. Griffith
@en
prefLabel
Obi Griffith
@ca
Obi Griffith
@en
Obi Griffith
@es
Obi Griffith
@fr
Obi Griffith
@ga
Obi Griffith
@sq
Obi L Griffith
@nl
Obi L Griffith
@sl
P1053
P-1286-2014
P106
P1153
7102837839
P19
P21
P2456
P27
P3373
P3829
P496
0000-0002-0843-4271